secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062019
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta reports Q3 net loss $25.6M; cash $278.4M; extends runway into 2026
-------------------------------------------------------------------------

- Net loss of $25.6M ($0.52 per share) for Q3 2023; R&D expenses $22.2M, G&A $7.1M.
- Cash and investments $278.4M as of Sep 30, 2023; cost containment extends cash runway into 2026.
- FDA cleared IND for NKX019 in lupus nephritis; first patient dosing expected H1 2024.
- Workforce reduced ~10%; operations centralization and manufacturing optimization underway.
- Clinical data updates in 2024: NKX101 AML, NKX019 NHL compressed dosing, LN.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017023062019/0000950170-23-062019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017023062019/nktx-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer